Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies the best way to give abiraterone acetate in treating
patients with castration-resistant prostate cancer. Abiraterone acetate is effective in
treating castrate resistant prostate cancer and is taken in the fasting state. However, the
body's absorption of abiraterone is increased with food intake. This study will test the
whether a lower dose of abiraterone taken with food has a similar effect on prostate specific
antigen (PSA) compared to full dose taken fasting.